
Results
21
Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.
21 companies
Ascendis Pharma
Market Cap: US$12.3b
Operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally.
ASND
US$199.22
7D
0.7%
1Y
58.1%
Alnylam Pharmaceuticals
Market Cap: US$59.7b
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference.
ALNY
US$452.74
7D
4.2%
1Y
71.1%
Madrigal Pharmaceuticals
Market Cap: US$12.3b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$528.94
7D
11.2%
1Y
67.8%
Exelixis
Market Cap: US$11.6b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$43.59
7D
8.0%
1Y
23.9%
Tempus AI
Market Cap: US$12.7b
Operates as a healthcare technology company.
TEM
US$71.10
7D
-13.6%
1Y
4.4%
Insmed
Market Cap: US$41.3b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$194.39
7D
4.0%
1Y
175.3%
BeOne Medicines
Market Cap: US$38.0b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$377.47
7D
17.4%
1Y
93.1%
Eli Lilly
Market Cap: US$885.2b
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally.
LLY
US$1,017.78
7D
9.9%
1Y
25.4%
BridgeBio Pharma
Market Cap: US$12.8b
A commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.
BBIO
US$66.22
7D
5.7%
1Y
167.1%
Ionis Pharmaceuticals
Market Cap: US$11.7b
A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
IONS
US$72.67
7D
-2.7%
1Y
92.4%
Exact Sciences
Market Cap: US$12.8b
Provides cancer screening and diagnostic test products in the United States and internationally.
EXAS
US$68.37
7D
-1.8%
1Y
34.8%
AbbVie
Market Cap: US$398.0b
A research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide.
ABBV
US$233.23
7D
7.6%
1Y
36.9%
Neurocrine Biosciences
Market Cap: US$14.7b
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally.
NBIX
US$146.85
7D
-4.5%
1Y
17.0%
Natera
Market Cap: US$28.5b
A diagnostics company, provides molecular testing services worldwide.
NTRA
US$209.50
7D
4.8%
1Y
30.1%
Royalty Pharma
Market Cap: US$22.5b
Operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
RPRX
US$39.59
7D
-2.1%
1Y
53.2%
Viatris
Market Cap: US$12.9b
Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.
VTRS
US$11.01
7D
2.4%
1Y
-15.3%
Medpace Holdings
Market Cap: US$17.0b
Provides clinical research-based drug and medical device development services in North America, Europe, and Asia.
MEDP
US$597.60
7D
-0.2%
1Y
65.1%
Elanco Animal Health
Market Cap: US$11.4b
An animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.
ELAN
US$22.05
7D
2.1%
1Y
55.4%
Revvity
Market Cap: US$10.7b
Provides health sciences solutions, technologies, and services.
RVTY
US$94.13
7D
1.7%
1Y
-21.4%
Teva Pharmaceutical Industries
Market Cap: US$28.8b
Develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
TEVA
US$25.83
7D
5.0%
1Y
52.5%
BioMarin Pharmaceutical
Market Cap: US$10.6b
A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
BMRN
US$55.32
7D
4.8%
1Y
-17.0%